ArticleSurgical endoscopy2026
Prognostic significance of extranodal extension for early postoperative recurrence following curative surgery in advanced gastric cancer.
Article in Surgical endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Adjuvant chemotherapy and lymph node examination interact to shape survival in older adults (≥ 75 years) with resected gastric cancer: a SEER-based propensity score-matched and competing-risk analysis.World journal of surgical oncology · 2026Article
- Metal-organic frameworks-mediated reactive oxygen species modulation in the tumor microenvironment of digestive system malignancies: latest advances.Frontiers in chemistry · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMore than half of recurrences in advanced gastric cancer (AGC) occur within 2 years of curative surgery. Identifying predictive factors for early recurrence is crucial for improving patient survival. We aimed to evaluate the impact of extranodal extension (ENE) and the largest metastatic lymph-node (LLN) size on early recurrence in patients with AGC.
methodsData of patients who underwent adjuvant chemotherapy after radical gastrectomy were extracted from the registry. Clinicopathological characteristics were compared according to ENE status and LLN size. Cox proportional hazard models were used to assess associations between ENE, LLN size, and oncologic outcomes.
resultsThis study included 244 patients (mean age, 61.4 ± 10.7 years; male, 75.0%). ENE positivity was significantly associated with higher T and N stages, and larger LLN size. In the univariable analysis, ENE (hazard ratio [HR]: 5.43, p < 0.001) and LLN size ≥ 5 mm (HR: 3.52, p = 0.001) were significant predictors of early recurrence. However, in the multivariable analysis, only ENE was an independent risk factor (HR: 3.34, p = 0.007). For 5-year RFS, ENE positivity (HR: 2.15, p = 0.003), higher T stage (HR: 1.93, p = 0.044), and advanced N stage (HR: 2.59, p = 0.007) were independent prognostic factors, whereas LLN size lost statistical significance. Similarly, ENE positivity remained an independent prognostic factor for OS (HR: 2.04, p = 0.015).
conclusionENE is a strong independent prognostic factor for early recurrence and long-term survival in AGC, whereas LLN size, despite its association with tumour aggressiveness, loses prognostic significance after multivariable adjustment, highlighting ENE's clinical relevance in risk stratification and postoperative management strategies.
Indexed as
Identifiers
41249532What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.